<DOC>
	<DOCNO>NCT01969084</DOCNO>
	<brief_summary>Investigators propose examine effect 12 week Linagliptin , diabetes drug , treatment inflammation well vascular mitochondrial function diabetic patient . Investigators hypothesize Linagliptin reduce proinflammatory state , improve endothelial function , increase blood flow muscle microcirculation level improve mitochondrial function . In study , investigator perform test evaluate function small large blood vessel employ ultrasound laser doppler technique . In addition MRI scan evaluate mitochondrial function lower extremity muscle rest exercise also employ . Forty subject Type 2 diabetes study twelve week half randomly assign receive linagliptin half receive placebo . All test perform begin end study .</brief_summary>
	<brief_title>The Effect Linagliptin Mitochondrial Endothelial Function</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Patients T2DM whose medical lifestyle treatment regimen stable expect change study period . Patients consider stable treatment regimen change type antidiabetic medication past 3 month and/or change blood glucose level cause see health care provider often usual precede three month . The diagnosis T2DM accord American Diabetes Association criterion . Subjects previously diagnose T2DM require confirmatory testing . Age 3070 year Patients insulin stable insulin regimen least 4 month prior enrollment . Patients antidiabetic treatment eligible stable change treatment plan next three month study . HBA1c â‰¤ 10.0 Patient unstable diabetes result hyperosmolar coma , DKA , and/or documented increase decrease HbA1c 2.0 % within previous 6 month Treatment DPP4 Inhibitors GLP1 agonist . Patients discontinue treatment least free 3month period . Severe proliferative retinopathy render subject legally blind Previously intermittent claudication diagnose severe peripheral arterial disease require intervention . History Deep Vein Thrombosis ( DVT ) within past 3 month . Significant limb swell due lymphedema Previous diagnosis severe gastroparesis diabeticorum due autonomic neuropathy necessitate hospital admission Presence nonhealing foot ulceration due severe peripheral diabetic neuropathy History pancreatitis Documented diabetic nephropathy manifest macroalbuminuria enrollment study , ( 2 3 urine specimen collect within 36 month period urine albumin &gt; 300 ug/mg creatinine accord ADA position statement ) Smokers . Smokers define subject report tobacco use three month study enrollment . Active uncontrolled cardiovascular disease follow : 1 . Myocardial infarction , angina within 12 month study participation 2 . Arrhythmia ( uncontrolled , highly symptomatic , require treatment lifethreatening ) . 3 . Patients congestive heart failure require pharmacologic management , particularly accompany hypoperfusion hypoxemia due unstable acute failure , increase risk lactic acidosis . 4 . Stroke transient ischemic attack within 12 month study participation 5 . Uncontrolled hypertension : SBP &gt; 180 mmHg DBP &gt; 105 mmHg ( 2 abnormal reading visit ) Liver disease ( AST , ALT Alk Phos level &gt; 2x upper normal limit ) time enrollment Renal disease ( creatinine &gt; 2 mg/dL and/or estimate GFR &lt; 30 mL/min , history dialysis , nephrotic syndrome ) time enrollment . Severe dyslipidemia ( triglyceride &gt; 600 mg/dL cholesterol &gt; 350 mg/dL ) Subjects hypertriglyceridemia may retested 23 week value fluctuate tremendously within day . In event retested value allow patient enrol , plan deviation submit CCI . Any serious chronic disease require active treatment . Pregnancy Lactation Females childbearing potential use effective form birth control determine investigator . Subjects follow medication : 1 . Systemic ( inhale ) Glucocorticoids 2 . Antineoplastic agent 3 . Rifampin Patient know history immunodeficiency disease , include positive HIV ( ELISA Western blot ) and/or positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result past . History drug alcohol abuse within 12 month prior dose evidence abuse indicate laboratory assay conduct screen baseline evaluation . Acute chronic metabolic acidosis , include diabetic ketoacidosis . History hypersensitivity reaction linagliptin ( urticaria , angioedema , bronchial hyperreactivity ) metformin . Contraindications MRI : Medically unstable hematologic , renal , hepatic dysfunction , cardiac pacemaker , Intracranial clip , metal implant , external clip within 10 mm head , Metal eye . Pregnant nursing woman Claustrophobia .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Type II Diabetes Mellitus</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Linagliptin</keyword>
	<keyword>Tradjenta</keyword>
	<keyword>Glucose</keyword>
</DOC>